ICU Medical (ICUI) investor relations material

Key financial guidance and macro assumptions

• EBITDA guidance for the year set at $400–$430 million, based on stable hospital census and no major changes in tariffs or currency rates.

• Fuel and commodity prices are a headwind, but exposure is reduced due to a joint venture structure in IV solutions.

• Mid-single-digit growth expected in both consumables and systems, with some seasonality and back-half weighting.

• Gross margin targeted at 41% in 2026, with improvements from manufacturing and logistics consolidation, and further expansion to 43% by 2027 despite tariff impacts.

• Free cash flow expected to improve as integration and remediation costs decline, with a goal to reach 2x leverage and return capital to shareholders.

Business segment performance and strategy

• Consumables segment shows consistent growth, driven by product marketing, pump wins, niche markets, and some pricing power.

• SKU rationalization in the Vital Care portfolio aims to improve profitability, with short-term impact on growth but stabilization expected.

• Pump segment growth is supported by new product launches (Plum Solo, Plum Duo), with a focus on upgrading an aging installed base and leveraging software integration.

• Ambulatory pump headwinds from an OEM customer are expected to resolve by year-end, potentially improving segment performance in 2026.

• Innovation in consumables is ongoing, with efforts to integrate safety features and workflow improvements across the portfolio.

Integration, portfolio management, and market outlook

• Smiths integration is in its final stages, with manufacturing, logistics, and IT consolidation nearly complete; benefits to margins and cash flow expected in the back half of the year.

• Portfolio management for non-core assets is ongoing, with a focus on economic efficiency and avoiding shareholder dilution.

• Competitive landscape in pumps is driven by the need to refresh aging devices, with new technology and software differentiation seen as key advantages.

• Regulatory submissions for new Medfusion and CADD pumps are progressing, with constructive feedback and expectations for future approvals.

• Software monetization is a strategic focus, aiming to capture annuity revenue streams alongside device sales.